Miguel Angel De Los Santos-La Torre

Miguel Angel De Los Santos-La Torre

Auto-generated profile, based on publicly available information

Miguel Angel De Los Santos-La Torre

Instituto Nacional de Salud del Niño, Lima, Peru

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2019 in Diabetes
Verified
Journal Article
Open access
PDF file
MJMatthew B Johnson
Matthew B Johnson
EFElisa De Franco
Elisa De Franco
SGSiri Atma W. Greeley
Siri Atma W. Greeley
LLLisa R. Letourneau
Lisa R. Letourneau
KGKathleen M. Gillespie
Kathleen M. Gillespie
MAMariyam AlBadi
Mariyam AlBadi
Identifying new causes of permanent neonatal diabetes (PNDM) (diagnosis <6 months) provides important insights into β-cell biology. Patients with Down syndrome (DS) resulting from trisomy 21 are four times more likely to have childhood diabetes with an intermediate HLA association. It is not known whether DS can cause PNDM. We found that trisomy 21 was seven times more likely in our PNDM cohort than in the population (13 of 1,522 = 85 of 10,000 observed vs. 12.6 of 10,000 expected) and none of the 13 DS-PNDM patients had a mutation in the known PNDM genes that explained 82.9% of non-DS PNDM. Islet autoantibodies were present in 4 of 9 DS-PNDM patients, but DS-PNDM was not associated with polygenic susceptibility to type 1 diabetes (T1D). We conclude that trisomy 21 is a cause of autoimmune PNDM that is not HLA associated. We propose that autoimmune diabetes in DS is heterogeneous and includes coincidental T1D that is HLA associated and diabetes caused by trisomy 21 that is not HLA associated.

1 January 2020 in Case Reports in Endocrinology
Verified
Journal Article
Open access
PDF file
MTMiguel Angel De Los Santos-La Torre
Miguel Angel De Los Santos-La Torre
CÁCarlos Manuel Del Águila-Villar
Carlos Manuel Del Águila-Villar
LLLuis Rómulo Lu-De Lama
Luis Rómulo Lu-De Lama
ONOswaldo Nuñez-Almache
Oswaldo Nuñez-Almache
ECEliana Manuela Chávez-Tejada
Eliana Manuela Chávez-Tejada
MCMartha Rosario Calagua-Quispe
Martha Rosario Calagua-Quispe
Schimmelpenning–Feuerstein–Mims syndrome (SFM), an epidermal nevus syndrome characterized by skin lesions, has an estimated incidence of 1 per 10 000 live births. Nevus sebaceous, the most common cutaneous lesion, and verrucous nevus, the less frequent lesion, are coupled with a wide range of extracutaneous manifestations. As part of these manifestations, rarely, central precocious puberty can arise. We report the case of a 1‐year‐5‐month‐old girl who presented to the Endocrinology and Metabolism Department with breast enlargement that began at one year of age, growth of pubic and axillary hair three months later, and vaginal bleeding that occurred five months later. During clinical examination, melanocytic nevi, with a diameter ranging from 3 to 5 mm, were noted on the face. Verrucous nevi of variable size with a tendency for coalescence following the lines of Blaschko and melanocytic nevi with a diameter ranging from 3 to 6 mm were observed on the right hemibody and on the left hemibody, respectively. Right asymmetry of the lower extremities was observed. Laboratory findings showed a significant increase in the levels of follicle‐stimulating hormone (FSH) and luteinizing hormone (LH) after the gonadotropin‐releasing hormone (GnRH) stimulation test; additionally, imaging demonstrated advanced bone age and pubertal changes in the internal genitals. Analyses of the H‐RAS, K‐RAS, and N‐RAS genes in the blood and in the skin were performed, and a missense mutation in exon 2 of the gene, H‐RAS c37G > C (p.G13R), was detected in the latter. Treatment with triptorelin, a GnRH analog, was initiated, and it gave good clinical response. Epidermal nevus syndrome has a wide and variable systemic involvement. Thus, it is important to consider the development of precocious puberty for a prompt diagnosis and to strategize a multidisciplinary approach from the beginning.

23 March 2022 in Pediatric Diabetes
Verified
Journal Article
Open access
THThomas I. Hewat
Thomas I. Hewat
TLThomas W. Laver
Thomas W. Laver
JHJayne A. L. Houghton
Jayne A. L. Houghton
JMJonna M. E. Männistö
Jonna M. E. Männistö
SASabah Alvi
Sabah Alvi
SFSarah Flanagan
Sarah Flanagan
Background Hyperinsulinism results from inappropriate insulin secretion during hypoglycaemia. Down syndrome is causally linked to a number of endocrine disorders including Type 1 diabetes and neonatal diabetes. We noted a high number of individuals with Down syndrome referred for hyperinsulinism genetic testing, and therefore aimed to investigate whether the prevalence of Down syndrome was increased in our hyperinsulinism cohort compared to the population. Methods We identified individuals with Down syndrome referred for hyperinsulinism genetic testing to the Exeter Genomics Laboratory between 2008 and 2020. We sequenced the known hyperinsulinism genes in all individuals and investigated their clinical features. Results We identified 11 individuals with Down syndrome in a cohort of 2011 patients referred for genetic testing for hyperinsulinism. This represents an increased prevalence compared to the population (2.5/2011 expected vs. 11/2011 observed, p = 6.8 x 10(-5)). A pathogenic ABCC8 mutation was identified in one of the 11 individuals. Of the remaining 10 individuals, five had non-genetic risk factors for hyperinsulinism resulting from the Down syndrome phenotype: intrauterine growth restriction, prematurity, gastric/oesophageal surgery, and asparaginase treatment for leukaemia. For five individuals no risk factors for hypoglycaemia were reported although two of these individuals had transient hyperinsulinism and one was lost to follow-up. Conclusions Down syndrome is more common in patients with hyperinsulinism than in the population. This is likely due to an increased burden of non-genetic risk factors resulting from the Down syndrome phenotype. Down syndrome should not preclude genetic testing as coincidental monogenic hyperinsulinism and Down syndrome is possible.

1 January 2016 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
MSMiguel Angel De Los Santos
Miguel Angel De Los Santos
CÁCarlos Manuel Del Águila
Carlos Manuel Del Águila
MRMaria Isabel Rojas
Maria Isabel Rojas
JFJuan Manuel Falen
Juan Manuel Falen
ONOswaldo Nuñez
Oswaldo Nuñez
MCMartha Rosario Calagua
Martha Rosario Calagua
Background: Central diabetes insipidus (CDI) is a heterogeneous disease caused by arginine vasopressin deficiency; its management implies a profound understanding of the pathophysiology and the clinical spectrum. The aim of the study was to describe the clinical characteristics that indicate organicity in children and adolescents with central diabetes insipidus treated at the Department of Endocrinology from The Child Health’s Institute during 2001 to 2013.Methods: Cross-sectional, retrospective study. 79 cases of patients diagnosed with CDI (51 males and 28 females) from 1 month to 16 years of age were reviewed. For the descriptive analysis, measures of central tendency and dispersion were used; groups of organic and idiopathic CDI were compared using χResults: The average age of patients was 8.1±4.2 years. Organic causes were intracranial tumors, 44 (55.7%), Langerhans cell histiocytosis (LCH), 11 (13.9%) and cerebral malformations in 7 (8.9%) patients, while the idiopathic group was 14 (17.7%) patients. Regarding clinical characteristics suggestive of organicity, headache (p=0.02) and visual disturbances (p=0.01) were found statistically significant. The anterior pituitary hormonal abnormalities were documented in 34 (52.3%) organic CDI patients. Furthermore, we did not find a significant difference in the average daily dose of desmopressin between patients with permanent vs. transitory CDI (0.81±0.65 vs. 0.59±0.62; p=0.363).Conclusions: The main clinical features suggestive of organicity in pediatric patients with central diabetes insipidus were headache and visual disturbances; furthermore, anterior pituitary hormonal abnormalities suggest an underlying organic etiology.

8 December 2022 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
MTMiguel Angel De Los Santos-La Torre
Miguel Angel De Los Santos-La Torre
CÁCarlos Manuel Del Águila-Villar
Carlos Manuel Del Águila-Villar
LLLuis Rómulo Lu-De Lama
Luis Rómulo Lu-De Lama
ONOswaldo Nuñez-Almache
Oswaldo Nuñez-Almache
ECEliana Manuela Chávez-Tejada
Eliana Manuela Chávez-Tejada
RTRosa María Tucto-Manchego
Rosa María Tucto-Manchego
Objectives Congenital hyperinsulinism (HI) is a heterogeneous clinical disorder with great variability in its clinical phenotype, and to date, pathogenic variants in 23 genes have been recognized. Hyperinsulinism-hyperammonemia syndrome (HI/HA) is the second most frequent cause of this disease that shows an autosomal dominant pattern and is caused by an activating mutation of the GLUD1 gene, which responds favorably to the use of diazoxide. HI/HA syndrome presents with fasting hypoglycemia; postprandial hypoglycemia, especially in those with a high protein content (leucine); and persistent mild hyperammonemia. Neurological abnormalities, in the form of epilepsy or neurodevelopmental delay, are observed in a high percentage of patients; therefore, timely diagnosis is crucial for proper management. Case presentation We report the clinical presentation of two Peruvian children that presented with epilepsy whose genetic analysis revealed a missense mutation in the GLUD1 gene, one within exon 11, at 22% mosaicism; and another within exon 7, as well as their response to diazoxide therapy. To the best of our knowledge, these are the first two cases of HI/HA syndrome reported in Peru. Conclusion HI/HA syndrome went unnoticed, because hypoglycemia was missed and were considered partially controlled epilepsies. A failure to recognize hypoglycemic seizures will delay diagnosis and adequate treatment, so a proper investigation could avoid irreversible neurological damage.

25 March 2025 in Revista Pediátrica Especializada
Verified
Journal Article
Open access
PDF file
RTRosa María Tucto-Manchego
Rosa María Tucto-Manchego
CÁCarlos Manuel Del Águila-Villar
Carlos Manuel Del Águila-Villar
LLLuis Rómulo Lu-De Lama
Luis Rómulo Lu-De Lama
ONOswaldo Núñez-Almache
Oswaldo Núñez-Almache
ECEliana Manuela Chávez-Tejada
Eliana Manuela Chávez-Tejada
PAPamela Miluska Azabache-Tafur
Pamela Miluska Azabache-Tafur
Objective: To determine the association between clinical/biochemical criteria of metabolic syndrome and alanine aminotransferase (alt) levels in patients attended in the Endocrinology and Metabolism service of the Instituto Nacional de Salud del Niño between January 2015 and December 2019. Materials and methods: An analytical, retrospective cross-sectional study based on medical records of patients between 10 and 18 years of age with overweight or obesity. Bivariate and multivariate statistics were used to determine the associations between overweight groups and ALT levels. Results: A 39.3% of the sample presented high ALT levels. However, ALT levels were higher in the group of patients with obesity (42.4%). Only patients with obesity and high ALT levels showed increased total cholesterol and LDL (p < 0.05). According to the multivariate model, high LDL would function as a predictor of high ALT in overweight pubescent and adolescent patients (PR = 1.89; 95 % CI: 1.16 - 3.10). Conclusions: High LDL was associated with high ALT levels, which could be an indicator of cardiovascular disease, probably due to liver involvement. Further longitudinal studies are still required to establish causal associations.